Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Expanding Opportunities for Real-World Evidence in Oncology

July 7th 2022

Real-world evidence is finding an expanded role in oncology, prompting experts to rethink how data are gathered on the day-to-day usefulness of drugs for regulatory decisions.

Safety of Cemiplimab for Basal Cell Carcinoma

July 7th 2022

Experts review the safety and toxicity data of anti-PD-1 antibody agent cemiplimab for basal cell carcinoma treatment.

Dr. Sullivan on the Examination of Tebentafusp in Uveal Melanoma

July 6th 2022

Ryan J. Sullivan, MD, discusses the examination of tebentafusp-tebn in uveal melanoma.

Monitoring Strategies for Basal Cell Carcinoma

July 6th 2022

Shahab Babakoohi, MD, describes his monitoring strategies for patients with basal cell carcinoma.

Systemic Therapy Options for Basal Cell Carcinoma

July 1st 2022

Dr Jennifer Atlas leads a conversation on systemic therapy options in basal cell carcinoma with a review of clinical trial data.

Dr. Erogolu on the Rationale for Investigating Patterns in BRAF+ Metastatic Melanoma

June 28th 2022

Zeynep Eroglu, MD, discusses the rationale for investigating patterns of outcomes in patients with metastatic melanoma harboring BRAF mutations.

Adjuvant Pembrolizumab Wins European Approval for Stage IIB/IIC Melanoma Following Complete Resection

June 24th 2022

The European Commission has approved pembrolizumab for adjuvant treatment of adult and adolescent patients 12 years and older with stage IIB or IIC melanoma who have undergone a complete resection.

Dr. Tawbi on the Safety of Relatlimab Plus Nivolumab in Melanoma

June 24th 2022

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in patients with metastatic or unresectable melanoma, according to data from the phase 2/3 RELATIVITY-047 trial.

Cobolimab Plus Dostarlimab Achieves Clinical Responses in Advanced Melanoma

June 24th 2022

Treatment with the combination of cobolimab and dostarlimab led to an overall objective response rate and immune-related ORR of 42.9% consisting of all partial responses in patients with advanced or metastatic melanoma.

Treatment Options for Locally Advanced Basal Cell Carcinoma

June 23rd 2022

Experts review the currently available treatment options for locally advanced basal cell carcinoma.

Referring Patients with Basal Cell Carcinoma to Medical Oncology

June 23rd 2022

Dr. Shahab Babakoohi explains when to refer a patient with basal cell carcinoma from a dermatology practice to a medical oncologist.

T-VEC Plus Pembrolizumab Generates Promising Responses, Safety in PD-1–Refractory Advanced Melanoma

June 20th 2022

Adding talimogene laherparepvec to pembrolizumab led to encouraging responses with a manageable safety profile in patients with advanced melanoma who progressed on prior anti–PD-1 therapy, most notably in the adjuvant setting, according to findings from the phase 2 MASTERKEY-115 trial.

Cosibelimab Continues to Show Promise in Locally Advanced Cutaneous Squamous Cell Carcinoma

June 16th 2022

The PD-L1 antibody cosibelimab was found to elicit an encouraging objective response rate in patients with locally advanced cutaneous squamous cell carcinoma who were not eligible to undergo curative surgery or radiation.

Quavonlimab/Pembrolizumab Combo Shows Modest Antitumor Activity in Advanced Melanoma

June 16th 2022

The combination of quavonlimab and pembrolizumab was found to be generally well tolerated and to have modest antitumor activity in patients with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor, according to data from a phase 1/2 trial (NCT03179436).

Clinical Scenario 1: A 74-Year-Old Man with Locally Advanced Infiltrative Basal Cell Carcinoma

June 15th 2022

Jennifer Atlas, MD, presents the clinical scenario of a man with locally advanced basal cell carcinoma.

Gibney Breaks Down the Evolving Treatment Landscape of Melanoma

June 15th 2022

Geoffrey T. Gibney, MD, discusses current treatment options for patients with melanoma, clinical trials that have explored different agents and combinations, and developing treatment options in uveal melanoma.

Overview of Basal Cell Carcinoma

June 15th 2022

Shahab Babakoohi, MD, describes the incidence patterns, options for testing and diagnosis, and risk stratification for basal cell carcinoma.

Nivolumab Plus Relatlimab Demonstrates Sustained PFS Benefit in Advanced Melanoma

June 6th 2022

Fixed-dose nivolumab plus relatlimab elicited continued progression-free survival benefit vs nivolumab alone in patients with treatment-naïve, unresectable or metastatic melanoma, according to updated results from the phase 2/3 RELATIVITY-047 trial.

Adjuvant Pembrolizumab Results in Significant DMFS Improvement Over Placebo in Stage II Melanoma

June 5th 2022

Adjuvant pembrolizumab was found to result in a significant improvement in distant metastasis-free survival compared with placebo, with a continued reduction in risk of recurrence and an acceptable safety profile, in patients with resected stage IIB or stage IIC melanoma.

FDA Lifts Partial Clinical Hold on NEON-2 Trial Evaluating Davoceticept Plus Pembrolizumab in Advanced Malignancies

May 24th 2022

The FDA has lifted a partial clinical hold on the phase 1 NEON-2 trial investigating the use of davoceticept in combination with pembrolizumab in adult patients with advanced solid tumors or lymphoma.